Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial

<div>Cancer pain: secondary analyses. % change from baseline average pain (Q5 BPI) Cumulative Proportion of Responders Analyses (ITT) at late postinjection period.</div>

Pain Research and Management

fig2

Figure 2

Figure 2: Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial 

Figure 2 | Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial 